Audited annual filings, TTM ratios and consensus forward estimates
Wall Street price targets and rating actions
Revenue disaggregation per 10-K filing
Annual filings (FY) with consensus forward estimates (hatched)
1255 daily bars · split adjusted
Current price $1.17
Latest analyst grade actions
| Date | Firm | Action | Previous | New grade |
|---|---|---|---|---|
| Mar 10, 26 |
Daily · Wilder smoothing
| HC Wainwright & Co. |
| maintain |
| Buy |
| Buy |
| Feb 5, 26 | Piper Sandler | maintain | Overweight | Overweight |
| May 21, 25 | UBS | maintain | Buy | Buy |
| May 9, 25 | HC Wainwright & Co. | maintain | Buy | Buy |
| Mar 7, 25 | HC Wainwright & Co. | maintain | Buy | Buy |
| Mar 7, 25 | Stifel | maintain | Hold | Hold |
| Mar 6, 25 | Jefferies | upgrade | Hold | Buy |
| Mar 6, 25 | Piper Sandler | maintain | Overweight | Overweight |
| Jan 27, 25 | UBS | maintain | Buy | Buy |
Classic floor pivots from 2026-10-23
Computed from daily OHLCV bars
| Indicator | Value | Type | Action |
|---|---|---|---|
| RSI (14) | 42.98 | Oscillator | Neutral |
| Stochastic %K (14, 3, 3) | 66.96 | Oscillator | Neutral |
| Williams %R (14) | -29.66 | Oscillator | Neutral |
| MACD (12, 26, 9) | -0.13 (Hist 0.03) | Oscillator | Buy |
| Average Directional Index (14) | 32.41 (+DI 19.1 / -DI 24.4) | Trend | Strong Sell |
| EMA 20 | 1.23 | MA | Strong Sell |
| SMA 20 | 1.18 | MA | Sell |
| EMA 50 | 1.48 | MA | Strong Sell |
| SMA 50 | 1.60 | MA | Strong Sell |
| SMA 200 | 1.83 | MA | Strong Sell |
TTM vs. 5-year historical average (annual ratios)
| Metric | ALXO | Historical (5Y) / ref | Status |
|---|---|---|---|
| P/E ratio (TTM) | -1.0x | -3.9x · sector 20.7x | Discount |
| Forward P/E (FY26E) | -2.1x | EPS est. -0.56 | Elevated |
| Price / Book | 1.2x | 2.1x | Discount |
| Price / Sales | — | — | n/a |
| EV / EBITDA | -1.9x | -2.9x | Discount |
| Return on equity | -90.3% | — | Weak |
| Gross margin | 0.0% | 0.0% | n/a |
| Debt / Equity | 0.07 | 0.10 | Conservative |
| Piotroski / Altman Z | 2/9 | Z -3.27 | Distress |
Discounted cash flow model
Free float vs. closely held shares
13F institutional holdings are not available in the current data plan.
SEC Form 4 filings
| Date | Insider | Role | Type | Shares @ price | Value |
|---|---|---|---|---|---|
| Aug 17, 26 | Lettmann Jason | director, officer: CHIEF EXECUTIVE OFFICER | S-Sale | 2,230 @ $1.93 | $4.30K |
| Aug 17, 26 | Wong Shelly | officer: SVP, FINANCE AND CAO | S-Sale | 573 @ $1.93 | $1.11K |
| Jul 1, 26 | Wong Shelly | officer: SVP, FINANCE AND CAO | S-Sale | 1,404 @ $2.04 | $2.86K |
| Apr 16, 26 | Knight Jeff E. | officer: Chief Dev & Operating Officer | A-Award | 800,000 @ $1.68 | $1.34M |
| Apr 16, 26 | Klencke Barbara | officer: Chief Medical Officer | A-Award | 100,000 @ $1.68 | $168.0K |
| Apr 13, 26 | Knight Jeff E. | 0 | — | ||
| Mar 19, 26 | Lettmann Jason | director, officer: CHIEF EXECUTIVE OFFICER | S-Sale | 12,311 @ $2.17 | $26.71K |
| Mar 19, 26 | Pinto Shelly | officer: SVP, FINANCE AND CAO | S-Sale | 903 @ $2.17 | $1.96K |
Stock news · updated daily
Achieved 40.3% ORR with evorpacept plus trastuzumab, ramucirumab and paclitaxel versus 26.6% for control, with response rates increasing to 63.6% versus 23.1% among patients with high CD47 expression and retained HER2-positive disease
BlackRock Inc. bought a new stake in shares of ALX Oncology Holdings Inc. (NASDAQ: ALXO) in the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 7,399,530 shares of the company's stock, valued at approximately $15,317,000. BlackRock Inc. owned 5.50% of ALX Oncology
SOUTH SAN FRANCISCO, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. ("ALX Oncology"; Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients' lives, today announced that ALX Oncology leadership will participate in fireside chats at three upcoming investor conferences.
5AM Venture Management LLC acquired a new position in shares of ALX Oncology Holdings Inc. (NASDAQ: ALXO) in the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm acquired 3,057,325 shares of the company's stock, valued at approximately $6,328,663,000. ALX Oncology makes up
Here is how ALX Oncology Holdings Inc. (ALXO) and Medpace (MEDP) have performed compared to their sector so far this year.
– On track for mid-2027 topline data readout from 80 patients in the Phase 2 ASPEN-09-Breast clinical trial evaluating evorpacept in combination with trastuzumab and chemotherapy in HER2-positive metastatic breast cancer – – Presented encouraging Phase 1b/2 breast cancer data at ESMO Breast Cancer 2026 that further validate a biomarker-driven development strategy for evorpacept – – Strong enrollment momentum in Phase 1 clinical trial of ALX2004 in EGFR expressing solid tumors with initial safety data on-track for 2H 2026 – – Strengthened leadership team with the appointments of Scott Garland as Chairman of the Board of Directors and Michael Listgarten as General Counsel – SOUTH SAN FRANCISCO, Calif., Aug. 06, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. ("ALX Oncology," Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients' lives, today reported financial results for the second quarter ended June 30, 2026, and provided a corporate update.
Reported EPS vs. consensus estimate
| Report date | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|
| Aug 6, 2026 | -0.14 | -0.13 | Beat 9.0% | — |
| May 8, 2026 | -0.15 | -0.17 | Miss -13.3% | — |
| Feb 27, 2026 | -0.38 | -0.42 | Miss -10.5% | — |
| Nov 7, 2025 | -0.37 | -0.41 | Miss -10.8% | — |
| Aug 12, 2025 | -0.46 | -0.49 | Miss -6.5% | — |
| May 8, 2025 | -0.47 | -0.58 | Miss -23.4% | — |
SEC EDGAR filings · last 12 months
| Form | Filed | Accepted | Document |
|---|---|---|---|
| SC 13D/A | Oct 16, 2026 | 2026-10-16 21:21:15 | View |
| 8-K | Oct 15, 2026 | 2026-10-15 16:55:47 | View |
| 4 | Aug 18, 2026 | 2026-08-18 17:51:24 | View |
| 4 | Aug 18, 2026 | 2026-08-18 17:50:21 | View |
| SC 13G/A | Aug 14, 2026 | 2026-08-14 16:23:46 | View |
| 10-Q | Aug 6, 2026 | 2026-08-06 16:01:43 | View |
| 8-K | Aug 6, 2026 | 2026-08-06 08:05:22 | View |
| SC 13G | Jul 27, 2026 | 2026-07-27 16:25:24 | View |
| 4 | Jul 6, 2026 | 2026-07-06 16:30:22 | View |
| 8-K | Jun 30, 2026 | 2026-06-30 16:01:15 | View |
Proxy statement (DEF 14A) disclosures
